As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic continue reading : HTA Council Preliminary Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
HTA Council Preliminary Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology
As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of levothyroxine sodium 12.5 micrograms (mcg) and 25mcg tablets for the management of hypothyroidism of any etiology. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from continue reading : HTA Council Preliminary Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology
HTA Council Final Recommendation on Multiple Micronutrient Supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and reduction of anemia among pregnant and lactating women (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 13 February 2026Date of notification to HTAC on the SOH decision: 02 June 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on multiple micronutrient supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and continue reading : HTA Council Final Recommendation on Multiple Micronutrient Supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and reduction of anemia among pregnant and lactating women (with Secretary of Health Decision)
HTA Council Final Recommendation on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) mutation test for the diagnosis of EGFR Mutations in patients with Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 18 March 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) Mutation Test for the diagnosis of EGFR mutations in patients continue reading : HTA Council Final Recommendation on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) mutation test for the diagnosis of EGFR Mutations in patients with Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
HTA Council Final Recommendation on erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), gefitinib (250 mg tablet and film-coated tablet), and afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation – postitive Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 12 March 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), Gefitinib (250 mg tablet and film-coated tablet), and Afatinib continue reading : HTA Council Final Recommendation on erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), gefitinib (250 mg tablet and film-coated tablet), and afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation – postitive Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)